Despite our strong belief in FMC’s robust business model and its ambition to help people with severe illnesses, we have the increasing impression that the company could be better run. Difficult to prove this but there seems to be a lot of talk and not much in the way of results. The disclosure is not always that good (e.g. p12 – Q3 presentation).
Q3 did not meet our expectations, but beat the street.
